Bal Pharma share news, announcements and annual reports
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Bal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, May 2006 on NSE
Last close ₹84.61down ₹1.56 (1.81%)BSE ₹84.35
Share price at the NSE close on 29 Oct 2026. Previous close ₹86.17.
29 Oct: open ₹86.50, high ₹86.89, low ₹84.12
52-week range of traded prices to 29 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹135 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.69
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.64
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.42%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,181
Bal Pharma share news and announcements
549 announcements, routine notices left out, newest first. Page 3 of 11.
Jul 2023
20 Jul · Meeting
Jun 2023
9 Jun · Legal
Exchange has sought clarification from Bal Pharma Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.1 Jun · Updates
May 2023
29 May · Results
Apr 2023
25 Apr · Rating
20 Apr · Business
4 Apr · Updates
Feb 2023
21 Feb · Updates
14 Feb · Updates
6 Feb · Board meeting
6 Feb · Results
Jan 2023
27 Jan · Board meeting
3 Jan · Updates
Dec 2022
16 Dec · Extra Ordinary Meeting
14 Dec · Extra Ordinary Meeting
Nov 2022
28 Nov · Related Party Transaction
18 Nov · Extra Ordinary Meeting
Oct 2022
27 Oct · Disclosure
3 Oct · General updates
Sep 2022
23 Sep
21 Sep · General updates
21 Sep · General updates
19 Sep · Meeting
Aug 2022
Jul 2022
4 Jul · General updates
Jun 2022
29 Jun · Legal
Exchange has sought clarification from Bal Pharma Limited with respect to announcement dated 30-May-2022 informing about appointment of Mr. Kotian Chittananda Damodar as Additional Director.On the basis of aforesaid announcement, the Company is required to provide/clarify the following:Change in directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), Auditor and Compliance Officer: 1. Disclosure of relationships between directors (in case of appointment of a director) 2. Reason for change viz. appointment, resignation, removal, death or otherwise 3. Brief profile (in case of appointment) 4. Date of appointment/cessation (as applicable) and term of appointment 5. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority The response of the company is awaited.14 Jun · Related Party Transaction
May 2022